2.65
+0.23(+9.50%)
Currency In USD
| Previous Close | 2.42 |
| Open | 2.48 |
| Day High | 2.66 |
| Day Low | 2.32 |
| 52-Week High | 6.75 |
| 52-Week Low | 1.11 |
| Volume | 2.62M |
| Average Volume | 2.32M |
| Market Cap | 347.93M |
| PE | -1.65 |
| EPS | -1.61 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 2.65 |
| Change | 0.23 |
If you invested $1000 in Prime Medicine, Inc. (PRME) since IPO date, it would be worth $172.41 as of June 27, 2025 at a share price of $2.65. Whereas If you bought $1000 worth of Prime Medicine, Inc. (PRME) shares 2 years ago, it would be worth $179.66 as of June 27, 2025 at a share price of $2.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
GlobeNewswire Inc.
May 19, 2025 12:31 PM GMT
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
GlobeNewswire Inc.
May 19, 2025 12:30 PM GMT
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels b
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
GlobeNewswire Inc.
Mar 18, 2025 11:00 AM GMT
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High levels of editing at the target site in preclinic